Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I found this really interesting and IMO, given the sample size that they're testing is relatively small (100 patients), the urgency for the drug, the years of testing it has already undergone and proof of it being safe and already effective against other coronviruses (hence why the broker note said the risk - reward here is "skewed significantly to the upside"), it's extremely likely that once they've done a few tests and if they begin to see positive results that correlate with the data they already have they could declare it a success and move to the next stage, as AZ did in your link.
Under such a scenario, that news could literally land at any time and considering that they are expected to have started testing last week and given that they have already raised the funds that enable them to quickly move to the next stage once it becomes clear they are ready to things would then move rapidly indeed.
This is good - although nothing to do with sng100 - its just showing that if good and works then can be fast tracked - so good news
SGD: That's what I thought.
"stopped for overwhelming efficacy" - means it's proved itself so effective that there's no point in continuing the current stage of a trial and therefore it is moved swiftly on to the next stage.
Some very strange reactions to this discussion. The only explanation that I can come up with is that they didn't understand the word 'efficacy'? Bye for now.
The CPAC machine that was made with Mercedes formula 1 has been fast tracked for clinical trails....could be passed by next Wednesday so I guess if sng001 is performing well it gets fast tracked too. Time to leave these to ride
my understanding is the pilot is 100.
then the full trial is 400. Note also 200 in the EEA (Europe!).
that was the link i found too - there are also some of the same details WHO website.
Yes, I noticed that 400 too, and wasn't sure exactly what it implied.
For reference :
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB
Hi SGD27,
I guess if they have independent people monitoring the data points as they come in, and it's looking positive & safe, then they might be able to scale up the trial. I see on the register the planned trial is up to 400 people.
Cheers.
Hi Milcait,
Well that was really my point, their trial was also double blind yet it stopped early. (But tell me if I've misunderstood!)
and don't forget it's a double-blind trial.
So until the results of the 100 pilot patients are in I don't think we'll get news on the results of the trial.
SNG's trial has a 14 day dosing period, and the pilot is 100 patients.
Assuming it started on 18 March, they may well be some way through with many of the patients, monitoring changes during the dosing period.
Not sure when we will hear of any results, probably not for a while yet, but details of the trial are publicly available on the Trials Register.
If the pilot trial is positive I'd imagine they will ramp it up very quickly and get huge support to do it....
this is a different story we are not talking Chronic Kidney Disease here ! this is a matter in the first instance life or death !! Covid-19
I don't know too much about Medicine trials but is Phase 3 just more patients? Or could that Phase be skipped if all is well?
I'm surprised no-one's mentioned this RNS by AZN today :
https://www.investegate.co.uk/astrazeneca-plc--azn-/rns/farxiga-ckd-trial-early-stop-for-positive-efficacy/202003300700070048I/
It's not directly relevant, and it's a Phase 3 trial (ours being Phase 2), but it's quite interesting as an example of a fast-tracked trial which has been "stopped for overwhelming efficacy". So it can happen. Like ours, it appears to be double-blinded, so I'm guessing it must have became obvious that 50% of the patients were improving dramatically.
Although I spotted it this morning I decided not to post during trading hours, as like everything else here it's sure to be misunderstood, quoted out of context, over-hyped and used as ramp-fodder.
Anyway, now that they've got this sorted out I expect AZN will be looking for something else to spend their time on, so maybe ... oops, sorry, doing it myself now.